July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Comparison of Geographic Atrophy lesion size measurements using RegionFinder and PAREXEL’s Alice image analysis platform
Author Affiliations & Notes
  • Russell Burns
    PAREXEL, Billerica, Massachusetts, United States
  • Justin Carpenter
    PAREXEL, Billerica, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Russell Burns, PAREXEL (E); Justin Carpenter, PAREXEL (E)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 3242. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Russell Burns, Justin Carpenter; Comparison of Geographic Atrophy lesion size measurements using RegionFinder and PAREXEL’s Alice image analysis platform. Invest. Ophthalmol. Vis. Sci. 2018;59(9):3242.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate differences in Geographic Atrophy (GA) lesion area and growth rate in fundus autofluorescent (FAF) images measured using Heidelberg’s RegionFinder (RF) compared to Alice and test the feasibility of using Alice for measuring GA lesion areas in clinical trials.

Methods : 20 subjects (88 total timepoints, single eye) were randomly selected from an industry sponsored trial for analysis in RF and Alice by the same reviewer. The raw FAF images were exported in the ‘.tiff’ format for analysis in Alice. When imported into Alice, these images were calibrated by utilizing the pixel to micron scale from RF. The reviewer utilized a freehand drawing tool in Alice without the need for any image registration.

Results : Average monthly lesion growth rates were 0.048 mm2 (Alice) and 0.058 mm2 (RF). Alice showed better growth rate agreement with RF images registered to baseline (0.052mm2) than with RF images not registered to baseline (0.076 mm2).

Conclusions : Alice can reliably measure and track GA lesion growth and is a viable alternative to RF in clinical trials.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×